테나야 테라퓨틱스(TNYA)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.68 (+1.44%), 시가총액 $0.19B, 52주 최저~최고 $0.43 ~ $2.10.
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regene
테나야 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
테나야 테라퓨틱스의 현재 주가는 $0.68 (+1.44%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
테나야 테라퓨틱스의 시가총액은 약 $0.19B입니다.
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gen